Processa Pharmaceuticals, Inc. (PCSA)

Between January 13, 2025, and January 9, 2026, the share price experienced a substantial decline. Around December 15, 2025, the company implemented a reverse stock split. The stock price increased around December 18, 2025, following a clinical update from a breast cancer study. Analysts increased the price target for PCSA to $25.50 around December 21, 2025. The company's annual shareholder meeting, initially adjourned on June 30, 2025, was reconvened and approved proposals on July 18, 2025. In June 2025, Processa entered into a licensing deal with Intact Therapeutics for PCS12852. The company conducted two equity offerings in the summer of 2025, raising approximately $9 million. Processa presented data at the ASCO Annual Meeting in 2025. The license agreement for PCS3117 was terminated around July 2025.

Direct demand seasonality for Processa Pharmaceuticals' drug products is not explicitly detailed, but there is an indication of seasonality in the company's stock performance. Historically, buying PCSA stock in May has shown the highest probability of a positive return, while January has exhibited the lowest probability. This seasonality pertains to stock market trends rather than the demand for its pharmaceutical products.

Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing drug products for serious medical conditions, operating within the Healthcare sector, specifically in the Pharmaceuticals and Drug Discovery industries. The company focuses on a regulatory science approach to develop Next Generation Chemotherapy (NGC) oncology drug products, modifying existing FDA-approved cancer drugs to improve efficacy and safety. Key product candidates include PCS6422 (NGC-Cap) for metastatic colorectal and breast cancer, PCS499 for ulcerative necrobiosis lipoidica and rare kidney diseases, PCS12852 for GI motility disorders, PCS3117 (NGC-Gemcitabine) which had its license agreement terminated, and PCS11T (NGC-Irinotecan) as a prodrug of irinotecan's active metabolite.

Processa Pharmaceuticals, Inc. is headquartered in Vero Beach, Florida, and maintains a corporate office in Hanover, Maryland, both in the United States. The information does not indicate a broader international geographic footprint for the company's operations or product distribution at this time.

Processa Pharmaceuticals' brand reputation has faced challenges, with TipRanks' AI Analyst "Spark" rating PCSA as "Underperform" due to financial challenges, a lack of revenue generation, ongoing losses, bearish technical indicators, and a reliance on external financing. H.C. Wainwright maintained a "Buy" rating but adjusted their price target downwards, acknowledging recent equity financing and future cash needs.

Processa Pharmaceuticals, Inc. has a mix of institutional and individual owners, with 23 institutional owners holding a total of 1,836,107 shares. Major institutional owners include Stonepine Capital Management, LLC, Geode Capital Management, LLC, and Vanguard Group Inc., among others. Key individual owners include James E. Besser, Justin W. Yorke, and George K. Ng, among others.